q3 earnings per share $6.05.
q3 adjusted earnings per share $6.82.
q3 revenue $4.1 billion.
revenue: q3 of $4.1 billion, versus $3.9 billion last year.
company raises full-year guidance.
qtrly diagnostics revenue for quarter was $2.62 billion, a decrease of (3.2%).
drug development revenue for quarter was $1.46 billion, an increase of 17.5% over $1.24 billion in q3 of 2020.
qtrly drug development revenue was $1.46 billion, an increase of 17.5%.
diluted eps: q3 of $6.05, versus $7.17 last year.
